Your GLP-1 Monitoring Timeline
A structured 4-node testing program that tracks your molecular response from pre-treatment through long-term maintenance. Each node is timed to capture critical phases of your GLP-1 therapy.
Four Nodes.
Every Critical Phase.
Each testing node is strategically timed to capture a distinct phase of your GLP-1 therapy journey.
Pre-Treatment Baseline
What's Tested
Baseline mRNA transcriptomic profiling to capture your pre-treatment molecular profile.
What You Learn
Your genetic predisposition to GLP-1 therapy and your molecular baseline — the starting point against which all future nodes are compared.
Receptor Binding
What's Tested
Follow-up mRNA panel focused on receptor binding markers.
What You Learn
Whether your GLP-1 medication is actually engaging your receptors and activating the expected metabolic pathways. This is the earliest molecular confirmation that therapy is working.
If pathway engagement isn't detected here, it may indicate the need for dosage adjustment or medication change — months before traditional labs would flag an issue.
Response Classification
What's Tested
Comprehensive mRNA panel with responder curve analysis.
What You Learn
Your responder classification — High, Good, Moderate, or Low responder — based on sustained transcriptomic patterns. This guides long-term dosage and therapy strategy.
By this point, your molecular data shows a clear trajectory. This is when your provider has the most actionable data for optimizing your treatment.
Maintenance
What's Tested
Annual mRNA surveillance panel.
What You Learn
Whether transcriptomic drift is occurring — early molecular signals that your therapy may be losing effectiveness, detectable before any physical weight regain occurs.
This ongoing surveillance catches relapse signals at the cellular level, giving you and your provider time to intervene proactively.
Testing Overview
| Node | Timing | What's Tested | What You Learn |
|---|---|---|---|
| 1 — Baseline | Before first dose | Baseline mRNA profiling | Genetic predisposition & molecular starting point |
| 2 — Receptor Binding | Week 2–4 | Follow-up mRNA panel | Receptor engagement & pathway activation |
| 3 — Response | Week 24–26 | mRNA + responder curve analysis | Responder classification (High / Good / Moderate / Low) |
| 4 — Maintenance | Annually (12+ mo) | Annual mRNA surveillance | Transcriptomic drift & early relapse signals |
All nodes include at-home mobile phlebotomy and secure dashboard delivery. Results delivered within 20–30 days.
Leading vs.
Lagging Indicators
Traditional Lab Markers
Blood chemistry snapshots that show what has already changed. Standard labs like lipid panels and HbA1c reflect accumulated changes over weeks to months. These are powerful markers, but they're reactive — they tell you what already happened.
Transcriptomic Monitoring
mRNA gene expression reveals what is actively changing at the cellular level. Transcriptomic shifts are visible within days to weeks of starting therapy — catching molecular changes before they ever surface on a standard panel. Proactive and predictive.
The OHL testing schedule is designed around the biology — testing at the moments when molecular changes are most detectable and most actionable.
Start Your Monitoring
Program
$1,050 for your complete first year — Nodes 1–3 series setup ($750) plus Node 4 maintenance ($300). $300/year ongoing for annual transcriptomic surveillance.
CLIA-certified · Nationwide mobile phlebotomy · Powered by Biomeme